There are many targeted therapy strategies for MC (Table 1), among which SCF/c-KIT is crucial for MC’s development and function, and TKIs, such as imatinib and nilotinib, can target MCs in some conditions, such as mastocytosis and allergies, by inhibiting the binding of SCF to c-KIT receptors [21]. Here, KITLG is linked to allergic disease.